• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DIA begins transition to new executive leadership

DIA begins transition to new executive leadership

December 10, 2012
CenterWatch Staff

DIA, a neutral, global, nonprofit association that provides knowledge resources across the full spectrum of medical product development, announced that Paul Pomerantz, worldwide executive director of DIA, will be leaving effective March 3, 2013, to assume the position of CEO for the American Society of Anesthesiologists.

In the next three months, Pomerantz will work closely with DIA's board of directors to execute a smooth transition that sustains the momentum the organization has achieved under his leadership.

"Paul has been an extraordinary executive director who will be sorely missed, but together we have built a strong foundation for continued growth," said Dr. Ling Su, president of DIA. "We are committed to continuing the implementation of our strategic plan, which is bringing quality programs and services to our members and stakeholders globally. We thank Paul for his contributions and wish him the best of success in his new position."

Under the leadership of Pomerantz, DIA has achieved rapid global expansion and significantly increased its stakeholder relationships—particularly among global health organizations, regulatory agencies and patient groups—driving its transformation into a world-class, knowledge-driven organization.

"This was a very difficult decision to make," Pomerantz said. "The last three years have been among the most fulfilling of my professional career. I am proud of what we accomplished, and confident that DIA's board of directors, staff and volunteers will continue our progress. My new position provides an exciting challenge to serve the needs of a leading medical association and its patients."

The DIA board of directors will announce plans for the executive director search in January.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing